Identification and correlation of cytologic criteria to histologic grade in canine cutaneous mast cell tumors by Morrison, Jo Ann
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2007
Identification and correlation of cytologic criteria to




Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Veterinary Medicine Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Morrison, Jo Ann, "Identification and correlation of cytologic criteria to histologic grade in canine cutaneous mast cell tumors"
(2007). Retrospective Theses and Dissertations. 14649.
https://lib.dr.iastate.edu/rtd/14649
Identification and correlation of cytologic criteria to histologic grade in canine cutaneous 











A thesis submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 




Major: Veterinary Clinical Sciences 
 
Program of Study Committee: 
Albert E. Jergens, Major Professor 
Claire Andreasen 

























All rights reserved. This microform edition is protected against 
    unauthorized copying under Title 17, United States Code.
ProQuest Information and Learning Company 
300 North Zeeb Road
P.O. Box 1346
     Ann Arbor, MI 48106-1346 






There have been innumerable people who have been instrumental in my 
professional and personal life: family, friends, colleagues and mentors.  This page is too 
short and their accomplishments too vast to be documented here.  However, they have my 
utmost admiration, respect, gratitude, and thanks.  You know who you are.  And to Sam, 
my Rhodesian Ridgeback, who lost his own battle with mast cell disease.  It was not for 
































TABLE OF CONTENTS 
 
 
CHAPTER 1. INTRODUCTION                                                                                        1 
 
CHAPTER 2. LITERATURE REVIEW                                                                             6 
 
CHAPTER 3. STUDY DESIGN AND MATERIALS AND METHODS                        23 
 
CHAPTER 4. RESULTS AND DISCUSSION                                                                 33 
 
CHAPTER 5. GENERAL CONCLUSIONS AND FUTURE DIRECTIONS                  43            
 


































CHAPTER 1.  INTRODUCTION 
 
 Mast cell tumors are the most common cutaneous tumors recognized in dogs, and 
are the second most common cutaneous tumors identified in cats.  Tumors may be limited 
to the skin and subcutaneous tissue, may metastasize to other sites, and may cause 
systemic, fatal  disease.  Several factors have been identified as prognostic indicators in 
animals with cutaneous mast cell tumors:  location of the tumor on the body, breed of the 
animal, stage of disease, presence or absence of systemic signs, and histologic grade of 
the tumor.  However, numerous studies have conflicting results which makes mast cell 
disease characterization and determination of prognosis problematic.  This remains a 
significant challenge in the clinical setting.   
Cytology, literally the study of cells, has long been recognized as a valuable 
component of the diagnostic evaluation of both internal and external lesions in humans 
and animals.  Specimen evaluation via cytology has several, well recognized, unique 
advantages in the clinical arena.  Cytologic specimens are relatively easy to obtain and 
diagnostic samples may be obtained by several methods.  Needle fenestration and fine 
needle aspiration are the most commonly employed methods to obtain specimens for 
cytologic analysis from cutaneous lesions.  These techniques are minimally invasive and 
associated with little to no patient morbidity, in contrast to surgical excision.  These 
techniques are also easy to perform and readily available to veterinary practitioners.  
Cytologic evaluation is relatively inexpensive, requires no specialized equipment, and 
results are rapidly available via interpretation by a cytopathologist.  Lastly, the 
information that can be obtained through cytology can facilitate future treatment planning 
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and may be crucial to patient outcome.  While cytology has been traditionally utilized for 
making a tentative diagnosis of mast cell tumors, the potential correlation of cytologic 
characteristics to histologic grade has not been fully investigated.       
Historically, histologic grade has been considered one of the most valuable 
factors, if not the gold standard, in determining prognosis for mast cell tumors.  The most 
commonly utilized histologic grading scheme was introduced by Patnaik et al in 1984.1  
This histologic scheme assigned mast cell tumors to one of three biologic grades (I, II, or 
III), based on defined morphologic criteria.  The Patnaik1 study also showed that 
prognosis worsened with increasing histologic grade.  Treatment protocols were limited 
to surgical excision.  In this original study of 83 dogs, the percentage of animals with 
grade I tumors surviving 1500 days was 83%; with grade II disease, the 1500 day 
survival percentage was 44% and with grade III disease, the 1500 day survival percentage 
was only 6%.  Thus, increasing histologic grade was inversely correlated with survival 
time.  
Present therapeutic options for cutaneous mast cell tumors involve surgical 
excision, chemotherapy, and radiation therapy, or a combination of treatment modalities.  
The histologic grade of a mast cell tumor plays a significant role in treatment decisions, 
as a more aggressive histologic grade warrants a more aggressive therapeutic plan.  This 
was clearly demonstrated in the Patnaik study1 where survival times significantly 
worsened with increasing histologic grade.  However, to obtain a histologic examination 
of a tumor, the tumor must be excised and submitted to the pathology laboratory for 
interpretation.  This requires surgical planning, general anesthesia, and post-surgical 
hospitalization.  The tissue must then be submitted for analysis, and histopathology 
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results are not as readily available compared to results obtained from cytology.  Once the 
tissue biopsy review is completed, it may be determined that additional, more invasive 
therapies are required for more aggressive neoplasms, which may increase patient 
morbidity.  This becomes an even larger consideration in those animals with recurrent 
disease or multiple mast cell tumors as these animals may undergo more morbidity than 
the patient with a single mass. 
Procurement of a cytologic specimen is a significantly less invasive and 
expensive procedure when compared to surgical excision for mast cell disease.  If 
cytology could be shown to correlate to histologic grade, this could provide to an 
attractive option to veterinarians and clients.  Cytology could, theoretically, be utilized 
for surgical planning and determining the need for clinical staging prior to surgery.  For 
example, if cytologic evaluation indicated a more benign tumor process, then a less 
aggressive surgical procedure with no additional staging might be warranted.  This could 
mean decreased patient morbidity, decreased hospitalization time and complication rates, 
and potentially decreased client costs.  Conversely, if characteristics associated with more 
aggressive disease were identified on initial cytology, then extensive surgical resection, 
complete clinical staging, or more aggressive adjuvant therapy might be indicated to 
induce clinical remission.   
A search of the literature demonstrated numerous contradictory findings regarding 
mast cell disease, especially related to prognosis.  These conflicting results translate into 
variability in clinical staging, treatment, and use of adjunctive therapy.  The literature 
review section is designed to highlight these contradictions and is organized based on the 
primary prognostic factor evaluated.  These sections are labeled as:  histologic grade, 
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clinical stage, treatment, tumor location, systemic signs, and breed.  Some studies have 
evaluated additional aspects of mast cell disease and these are listed in the literature 
review as:  cellular proliferation indices, Grade II mast cell tumors, cellular proliferation 
indices and histologic grade, nuclear morphometry, and cytologic correlation with 
histopathology.  Lastly, there is a brief mention of the feline aspects of mast cell disease.  
  The aim of the present study was to identify cytologic criteria of mast cell tumors 
that correlate to their histologic grade using the Patnaik1 scale.  The potential significance 
of this correlation could be demonstrated clinically in reduced patient morbidity and 
improved clinical management.  To aid in understanding for the reader, several terms 
used commonly during oncology discussions, and utilized in this thesis are briefly 
defined below.   
Term Definitions:* 
Cytology: the microscopic study of cells. 
Cytospin: a method for evaluation of cytology samples whereby samples are placed in a 
centrifugation chamber and cells are concentrated on a glass slide. 
Disease free interval: time from initial treatment of tumor to relapse or recurrence of 
tumor. 
Fine needle aspiration: one of the methods to obtain a cytologic sample where a needle 
with attached syringe is advanced into the target tissue.  While the tip of the needle is 
within the tissue, negative pressure is produced in the needle and syringe and cells are 
drawn into the needle.  Cells are then expelled from the needle hub onto a glass slide for 
analysis. 
Histology: the anatomic evaluation of microscopic tissue structure and composition. 
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Histopathology: the histologic evaluation of diseased tissue. 
Immunohistochemistry: the process of identifying particular cellular antigens via 
specific antibody markers, often used in the diagnosis of cancer. 
Lesion: any abnormality involving any tissue due to disease or injury. 
Mast cell: a granulated, connective tissue cell that is responsible, in part, for mediation of 
inflammatory reactions.  Granules contain and may release substances such as histamine, 
heparin, and proteolytic enzymes.  A mast cell may be a normal component of tissue; an 
infiltration of mast cells in a cutaneous nodule is a mast cell tumor. 
Mitosis: the process of cellular division. 
Needle fenestration: a method to obtain a cytologic sample where a needle is directed 
into the target tissue and advanced in several different directions while still contained 
within the tissue.  Cells that have collected in the needle are then expelled onto a glass 
slide for analysis. 
Pathology: the study of disease. 
Survival time: time from treatment of tumor to eventual death of the animal (from tumor 
or from any cause). 
Tumor: a new growth of abnormal tissue which may be benign or malignant. 
*Definitions were obtained / modified from Dorland’s Illustrated Medical Dictionary, 








Histologic grade  
 The seminal work that describes the histologic grading system used to this day for 
the diagnosis of mast cell tumors was done by Patnaik, Ehler, and MacEwen (1984).1  In 
this study, a new histologic grading system was developed that was notably different 
from the system, described by Bostock (1973)2 that had been used previously.  The most 
notable difference was in the assignment of tumor grades, in that the Patnaik1 system 
completely reversed the grading scale for mast cell tumors.  The current system for 
defining mast cell tumors describes three histologic grades of tumors.  Grade I tumors are 
well differentiated, low grade tumors that contain a uniform population of mast cells.  
There is minimal extension of tumor cells beyond the skin and little evidence of edema or 
necrosis.  Mitotic cells are not present in grade I tumors.  Grade II tumors have 
intermediate differentiation.  Mast cells are more variable in size and shape, extend 
somewhat deeper into the tissue, and may have associated edema and necrosis.  Mitotic 
cells may be present, but are rare.  Grade III tumors contain the most undifferentiated 
mast cells.  These tumors extend deeply into surrounding tissues and commonly are 
associated with edema, necrosis, and hemorrhage.  Mitotic cells are commonly observed 
in grade III mast cell tumors.  In addition to defining histologic criteria of different tumor 
grades, the Patnaik1 study also demonstrated distinct differences in 1500 day survival 
times between the three histologic grades of mast cell tumors.  This was one of the 
earliest studies that demonstrated the inverse correlation between histologic grade and 
long-term prognosis.  The correlation of histologic grade to prognosis was also 
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investigated by Thamm, Mauldin, and Vail (1999)3 in a study of 41 cases of canine mast 
cell tumors.  Similar to Patnaik,1 histologic grade was shown to be a significant 
prognostic factor in both univariate (p < 0.05) and multivariate (p < 0.001) analysis of the 
dogs studied.  In another investigation, Turrel, Kitchell, and Miller et al (1988)4 evaluated 
prognostic factors for mast cell tumors in 85 dogs, and showed that histologic grade 
significantly influenced survival rate (p = 0.006).  While histologic examination of biopsy 
specimens continues to be an extremely important determinant for mast cell tumor 
prognosis, there may be considerable variability in the interpretation of the histologic 
examination.  For example, Northrup, Harmon, and Gieger et al (2005)5 showed 
significant interobserver variability between pathologists when they independently 
reviewed a set of 60 mast cell tumors.  In this study, there was significant (p < 0.001) 
variation among 10 pathologists in assigning the same histologic grade to mast cell 
tumors.  Indeed, all 10 pathologists at one institution agreed on the histologic grade for 
only 4 / 60 tumors, and 6 tumors were assigned all 3 grades by different pathologists.  
While the value of histology as a prognostic indicator has been shown, it would appear 
that agreement on histologic grade may be somewhat open to interpretation.  Thus, it may 
be difficult to provide an accurate prognosis for all mast cell tumors on the basis of 
histologic grade alone.   
 
Clinical stage 
Clinical stage, which may be described as the extension of disease to involve 
regional lymph nodes or other metastatic sites, has also been documented to be an 
important prognostic indicator.  A clinical staging system, defined by the World Health 
 8 
Organization, is frequently utilized, in various modifications, in mast cell tumor 
evaluation.6  This staging system is summarized in Table 1. 
Table 1. World Health Organization Clinical Staging System.6 
Stage Clinical Description 
0 One dermal tumor, incompletely excised, without regional lymph node 
involvement 
1 One dermal tumor, without regional lymph node involvement 
2 One dermal tumor, with regional lymph node involvement 
3 Multiple dermal tumors or a large, infiltrating tumor, with or without regional 
lymph node involvement 
4 Any tumor with distant metastasis, including blood or bone marrow involvement, 
or tumor recurrence with metastasis 
 
Turrel, Kitchell, and Miller et al (1988)4 performed one of the earliest studies that 
investigated prognostic factors associated with clinical disease of mast cell tumors.  In a 
study of 85 dogs, clinical stage was found to be negatively correlated to median survival 
time.  Dogs with clinical stage 0 were shown to live significantly longer than dogs having 
a more advanced clinical stage (p < 0.001).  In a contrasting study, Chaffin and Thrall 
(2002)7 found that dogs with stage 2 mast cell disease had similar median survival times 
(1240 days) when compared to the median survival times of dogs with stage 0 disease 
(1200 days) previously reported by Turrel.4  It is important to realize that differences in 
results obtained by these separate studies could in part be explained by differing staging 
and treatment protocols used by these authors.  There is still controversy regarding the 
optimal procedures that are appropriate for clinical staging (example, bone marrow 
aspiration versus buffy coat evaluation of peripheral blood, or fine needle aspiration of 
the spleen and liver) in animals with cutaneous mast cell disease.  A study by Finora, 
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Leibman, and Fettman et al (2006)8 compared fine needle aspirates of liver and splenic 
tissues of normal dogs to dogs with cutaneous mast cell tumors.  Healthy dogs were 
shown to have mast cells in both liver and splenic aspirates, similar to diseased dogs, 
thus, bringing the value of these protocols used for clinical staging into question.  
Additionally, McManus (1999)9 evaluated peripheral blood and buffy coat smears for 
mast cells in dogs with and without mast cell tumors in a study to further investigate the 
prevalence of systemic mast cell disease.  Of the 120 cases that had mast cells in either a 
peripheral blood smear, buffy coat smear, or both, 94 dogs did not have mast cell tumors.  
This translated into 95.5% of peripheral blood smears that contained mast cells were 
obtained from dogs that did not have mast cell disease.  Also, when considering buffy 
coat smears, dogs that did have mast cell tumors had an average of 71.4 mast cells / buffy 
coat while dogs that did not have mast cell tumors had an average of 276.2 mast cells / 
buffy coat.  This study showed that mastocytemia is seen in conjunction with other 
disease states (e.g., inflammatory conditions, anemia).  Clearly, there is a lack of uniform 
staging criteria that confounds the clinical evaluation of animals with mast cell disease.  




Concurrent with the difficulty in uniform clinical evaluation is the non-
standardized treatment protocols employed for animals with mast cell tumors.  It is 
noteworthy that therapy recommendations may change over time, so animals with 
relatively similar disease burdens (clinical stage) may receive very different treatments 
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and hence have disparate survival times.  This makes evidence based determination of 
clinical management strategy  problematic.  Historically, surgery has been considered the 
mainstay of treatment and wide surgical excision has long been recommended for 
cutaneous mast cell tumors.  Interestingly, the common, historical recommendation of a 3 
centimeter surgical margin around the tumor does not appear to have any basis in the 
veterinary literature.  A study by Simpson, Ludwig, and Newman et al (2004)10 
prospectively evaluated 21 dogs histologically diagnosed with 23 cutaneous grade I and 
grade II mast cell tumors.  Tissue was marked at 1, 2, and 3 centimeter margins from the 
tumor and evaluated for completeness of surgical excision.  All grade I tumors were 
shown to be completely excised at all margins.  Of the grade II tumors, 75% were 
completely excised at the 1 centimeter margin and 100% were completely excised at the 
2 centimeter margin.  Thus, pre-operative knowledge of tumor histologic grade has the 
potential to impact surgical planning and patient morbidity.  Other investigations have 
shown that the adequacy of surgical excision may be open to interpretation.  In another 
study, Weisse, Shofer, and Sorenmo (2002)11 defined a “clean” (disease-free)  surgical 
margin as a 1 to 2 millimeter distance from tumor cells to normal tissue edge in 4 lateral 
margins.  However, Gieger, Northrup, and Wall (2005)12 defined a clean margin as 
requiring at least 10 millimeters distance between tumor cells and normal tissue.  The 
interpretation of the surgical margin and other factors such as histologic grade of the 
tumor, influence the decision for additional, or adjunctive therapy.  Measures such as 
survival time and disease free interval may be significantly influenced by treatment 
modality.  Treatment decisions in veterinary patients are also influenced by the 
availability of treatment modalities (radiation therapy units, chemotherapy 
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administration) and the associated costs of implementing such therapies.  The variability 
in treatment protocols reported in the literature, as for clinical staging, makes 
comparisons of treatment efficacy and prognosis between studies difficult.  This 
emphasizes the need to identify independent prognostic indicators that are minimally 
influenced by variables such as treatment.  
 
Tumor location 
Tumor location has also been reported to influence prognosis.  Gieger, Theon, and 
Werner et al (2003)13 retrospectively evaluated 24 mast cell tumors on the muzzle of 
dogs.  In this study, a larger percentage of tumors from the muzzle were histologically 
classified as grade III (29%) as compared to mast cell tumors localized to other anatomic 
locations.  Dogs with grade III tumors had significantly shorter survival times (p = 
0.0027) than did dogs with tumors classified as grade I or grade II, as would be expected 
with a more biologically aggressive form of the disease.  Similarly, Turrel, Kitchell, and 
Miller et al (1988)4  showed that tumor location was an important prognostic variable, 
with tumors on the extremities having significantly longer survival times (p < 0.004) than 
tumors located on the trunk.  However, a study by Sfiligoi, Rassnick, and Scarlett et al 
(2005)14 showed no significant difference in survival times or disease free intervals in 
124 dogs with mast cell tumors in the inguinal / perineal regions compared to dogs with 






The presence or absence of  systemic signs of mast cell disease is another area 
that has been associated with survival.  The ability of mast cell tumors to cause systemic 
signs relates to the contents of the mast cell granules involving histamine, heparin and 
proteolytic enzymes.  Release of these substances may result in gastroduodenal ulceration 
and perforation, which may be a significant cause of morbidity and mortality.  Other 
systemic signs of mast cell disease include delayed wound healing, tissue ulceration and 
edema, hypotension, and coagulation abnormalities.  A study by Mullins, Dernell, and 
Withrow et al (2006)15 of 54 cases of cutaneous mast cell tumors revealed that the 
presence of systemic signs at the time of diagnosis was the only variable associated with 
significantly shorter disease free intervals (p = 0.023).  Other variables that were 
evaluated in this study, including incomplete tumor excision, local recurrence, and large 
tumor size were not found to be significantly associated with disease outcome.  O’Keefe, 
Couto, and Burke-Schwartz et al (1987)16 also described systemic signs in 16 dogs with 
mast cell tumors.  Eighty eight percent of the dogs in this study died or were euthanized 
as a result of their clinical disease.  Common clinical signs in these dogs included 
anorexia, vomiting, diarrhea, edema, ulceration, and abscessation.  The dogs in that study 
also had a higher percentage of grade III tumors (77%), compared to dogs in other 
studies.  These accumulated data provide consistent  evidence that grade III tumors have 
a more aggressive biologic behavior; thus it is not surprising that animals with grade III 
tumors might have more systemic signs.   
One of the proposed mechanisms for the development of systemic signs of mast 
cell disease is the release of histamine from mast cell granules causing a generalized 
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increase in plasma histamine levels.  Fox, Rosenthal, and Twedt et al (1990)17 measured 
histamine levels in dogs with mast cell tumors and in normal dogs.  These authors found 
that tumor bearing dogs had significantly higher levels of histamine as compared to 
healthy controls.  However, plasma histamine levels in dogs with mast cell tumors did not 
correlate to clinical disease stage, tumor volume, or histologic grade of the tumor in this 
study.  Furthermore, no relationship could be detected between plasma histamine levels 
and disease progression.  In contrast, a study by Ishiguro, Kadosawa, and Takagi et al 
(2003)18 showed a positive association between plasma histamine levels and disease 
progression in dogs with mast cell tumors.  In this small study of 11 dogs, there was no 
difference noted in initial plasma histamine concentration between affected dogs and 
normal controls.  However, significant increases in plasma histamine levels in animals 
with mast cell tumors were noted with clinical disease progression (p = 0.003).  Lastly, 
dogs with terminal disease were noted to have the most significant elevations in plasma 
histamine, and these animals were refractory to anti-histamine therapy.   
 
Breed 
Certain breeds of dogs have been shown to have a higher incidence of mast cell 
tumors suggesting breed predispositions for the development of disease.  In Patnaik’s 
study,1 Boxers showed an increased prevalence, representing 14% of the total cases.  The 
most common pure breeds affected in another study15 were the Labrador retriever (20%) 
and the Boxer (11%).  It is generally accepted that brachycephalic breeds (Boxers, 
Boston terriers) have an increased incidence of mast cell tumors.  Shar-Peis have also 
been shown to have an increased incidence of mast cell tumors as reported by Miller 
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(1995).19  In this study, Chinese Shar Peis were the most common breed, less than 2 years 
of age, diagnosed with mast cell tumors.  Similarly, grade III tumors diagnosed in young 
dogs less than 2 years of age, were most prevalent in Shar-Peis.  Despite these 
observations, it is still controversial as to what effect breed predisposition might have on 
prognosis. 
 
Cellular proliferation indices 
Most recently, other factors correlating to prognosis have been identified in an 
attempt to avoid the limitations and contradictory findings evidenced in previous studies.  
For example, silver nucleolar organizing regions (AgNOR), proliferating cell nuclear 
antigen (PCNA), and Ki-67 are all indicators of cellular proliferation and have prognostic 
significance.  Another factor, c-kit, is a proto-oncogene that has also been evaluated as a 
prognostic variable.  The increased expression of these factors corresponds to increased 
cellular activity, and presumably, more aggressive biologic behavior.  The expression of 
these factors in tumor tissue, identified by immunohistochemical staining on 
histopathology samples, has been shown to correlate with shortened survival times and 
worsening prognosis in different studies.  Bostock, Crocker, and Harris et al (1989)20 
showed significant correlations between AgNOR scores, histologic grade, and disease 
outcome in a study of 50 mast cell tumors in dogs.  Nucleolar organizer regions (NOR) 
act as sites for transcription of rRNA (ribosomal RNA, which is involved in the process 
of protein synthesis).  As cellular proliferation increases, the cell cycle shortens and RNA 
synthesis increases.  In this study, as histologic grade increased, AgNOR expression also 
increased and increased AgNOR expression correlated to shortened survival time.  
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Simoes, Schoning, and Butine (1994)21 also evaluated AgNOR counts and PCNA 
labeling, via immunohistochemistry, along with histologic grade and mitotic index in 122 
canine mast cell tumors.  Proliferating cell nuclear antigen (PCNA) is a protein required 
for DNA synthesis and is associated with cellular growth fraction.  Their results 
demonstrated that AgNOR and PCNA staining was significantly increased in recurrent 
versus non-recurrent mast cell disease and also in metastatic versus non-metastatic mast 
cell disease.  In a separate investigation, Preziosi, Morini, and Sarli (2004)22 investigated 
the expression of c-kit in 31 cutaneous mast cell tumors in dogs.  The c-kit is a proto-
oncogene that encodes for a type III tyrosine kinase protein (KIT).  This protein functions 
as a receptor for stem cell factor, also known as mast cell growth factor, that stimulates 
mast cell growth and differentiation.  Their study demonstrated a highly significant 
correlation (p < 0.00000) between c-kit expression and histologic grade.  Abadie, 
Amardeilh, and Delverdier (1999)23 investigated the expression of Ki-67 in 120 mast cell 
tumors.  The role of Ki-67 is not completely elucidated; however, it is thought to be 
associated with nucleolar RNA.  In this study, Ki-67 expression was shown to be 
significantly higher in dogs that died of mast cell disease (p < 0.001).  The expression of 
Ki-67 was also significantly different between tumors when tumors were grouped by 
histologic grade.  Ki-67 expression increased as tumor histologic grade increased.  
Another indicator of potential biologic activity is intratumoral microvessel density 
(IMVD) which was investigated by Preziosi, Sarli, and Paltrinieri (2004)24 in an 
evaluation of 32 cutaneous mast cell tumors.  In this study, tumor microvasculature was 
identified by immunohistochemistry and its density was shown to negatively correlate 
with survival time (p = 0.046).  Another factor that has been evaluated for biologic 
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behavior as it relates to prognosis is DNA ploidy status.  Ayl, Couto, and Hammer et al 
(1992)25 investigated DNA ploidy in 44 canine mast cell tumors.  The DNA content of 
neoplastic cells was measured via flow cytometry and tumors were determined to be 
either diploid or aneuploid.  The rationale for this study was diploid status would indicate 
relatively consistent DNA content among the nuclei of tumor cells while aneuploid status 
would indicate more variable DNA content within the nuclei of tumor cells, suggesting 
biologic aggressiveness.  Results from this investigation showed that aneuploid status 
was more common in animals with advanced mast cell disease.   
One advantage that utilizing various cellular proliferation indices provides is that 
the evaluation of these factors is considered to be more objective than other currently 
utilized prognostic criteria.  While studies are currently ongoing, these factors may prove 
to be important for overall disease prognosis and may provide an advantage over 
traditional histopathologic grading.  However, their routine use by histopathology 
laboratories on a widespread basis is yet to be performed. 
 
Grade II mast cell tumors 
The majority of mast cell tumors are identified as grade II on histologic 
evaluation.  Cahalane, Payne, and Barber et al (2004)26 reviewed 68 cases of mast cell 
tumors and found 64 (94%) of tumors were histologically classified as grade II tumors.  
Sfiligoi, Rassnick, and Scarlett et al (2005)14 evaluated 124 cases of mast cell tumors.  In 
that study, 82 (66%) of tumors were classified as grade II.  Scase, Edwards, and Miller et 
al (2006)27 retrospectively analyzed 121 dogs with mast cell disease.  Eighty six of the 
121 dogs (71%) were classified as having grade II tumors.  Even in smaller studies, the 
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majority of mast cell tumors are identified as grade II tumors.  Gerritsen, Teske, and 
Kraus et al (1998)28 evaluated 17 dogs with mast cell tumors, and 12 / 17 (71%) were 
diagnosed with grade II disease.  In a study of 22 dogs by Rassnick, Moore, and Williams 
et al (1999),29 10 dogs (53%) were determined to have grade II tumors.  Michels, Knapp, 
and DeNicola et al (2002)30 retrospectively reviewed 31 cases of mast cell tumors.  In 
that study, 20 / 31 (65%) of tumors received a histologic classification of grade II. 
The significance that the majority of mast cell tumors receive a histologic 
classification of grade II is clear when considering their diverse biologic behavior.  
Biologic behavior of these tumors has been shown to vary widely with regards to local 
recurrence rates, development of additional cutaneous disease, and metastatic rates.  
Weisse, Shofer, and Sorenmo (2002)31 evaluated 31 dogs with grade II mast cell tumors 
that had complete surgical excision as determined by histopathology.  In that study, the 
local recurrence rate was 11% and the rate of distant tumor recurrence (regional lymph 
node, new cutaneous or other sites) was 22%.  In a separate study,32 thirty two dogs with 
grade II mast cell tumors that had incomplete surgical excision and follow up radiation 
therapy at the surgical site were evaluated prospectively.  Four percent of dogs had local 
recurrence of mast cell disease and 4% had fatal metastatic mast cell disease.  
Additionally, Seguin, Leibman, and Bregazzi et al (2001)33 retrospectively evaluated fifty 
five dogs that had complete surgical excision of grade II tumors.  These data showed that 
5% of tumors recurred locally, 11% developed mast cell tumors at a distant cutaneous 
location, and another 5% developed metastatic disease. Furthermore, Poirier, Adams, and 
Forrest et al (2006)34 retrospectively reviewed 45 cases of grade II tumors having 
incomplete surgical excision followed by local radiation therapy at the surgical site.  
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Local tumor recurrence was documented in less than 7 months for 6.7% of cases; 
metastatic disease developed in 4.4%, and distant cutaneous disease developed in 31%.  
Taken together, these accumulated studies would seem to demonstrate the variability in 
biologic behavior and disease progression observed with grade II mast cell tumors.  It is 
therefore reasonable to investigate other factors, beyond histologic grade alone, that may 
play a significant role in predicting disease progression in animals with grade II mast cell 
tumors. 
 
Cellular proliferation indices and histologic grade 
 Applying PCNA, AgNOR, and Ki-67 tissue staining may allow grade II mast cell 
tumors to be more specifically evaluated.  An initial study by Bergman, Monette, and 
Northrup et al (2005)35 designated grade II mast cell tumors into low, medium, or high 
categories, based on their staining intensity for PCNA, AgNOR, and Ki-67.  These 
authors showed that increased expression of these proliferation markers was positively 
associated with the development of metastatic disease.  In addition, the up-regulated 
expression of these markers predicted development of metastatic disease better than 
histologic grade and was negatively associated with survival.  Even indirect measures of 
cellular proliferation may prove useful for delineating grade II mast cell tumors.  
Romansik, Reilly, and Kass et al (2007)36 retrospectively reviewed histopathology 
samples from 148 mast cell tumors for their mitotic activity.  The mitotic index was 
determined by number of mitoses / 10 high powered fields and the region of the tumor 
with the highest overall mitotic activity was used for histologic evaluation.  The results 
showed significant relationships between mitotic index and histologic grade, and between 
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increasing mitotic index and the risk for metastatic disease.  Also, mitotic index was 
shown to be predictive of survival time for animals with grade II mast cell tumors (p < 
0.001).   Lastly, a study by Seguin, Besancon, and McCallan et al (2006)37 investigated 
AgNOR, PCNA, and Ki-67 staining in a review of 30 cutaneous grade II mast cell tumors 
in dogs.  The combination of PCNA and Ki-67 scores were shown to be significant for 
prediction of local tumor recurrence.  The presence of local tumor recurrence was 
negatively associated with disease survival.   
 
Nuclear morphometry 
As previously described, obtaining specimens for cytologic evaluation has several 
advantages over obtaining specimens for histopathology.  One salient advantage is the 
ability to obtain important information about a tumor via this minimally invasive 
procedure.  While cytologic diagnosis of mast cell tumors has been shown to have 100% 
correlation with the histopathologic diagnosis (Griffiths, Lumsden, and Valli (1984)),38 
there have been few attempts to correlate specific cytologic (nuclear or cytoplasmic) 
criteria to histopathologic grade.  De Vico, Sfacteria, and Maiolino et al (2002)39 used an 
automated nuclear morphometry system to compare morphologic characteristics of 
cytology samples to histopathology samples from different spontaneous tumors in dogs.  
The automated system used a computerized image analysis system to load cellular images 
into a digital memory system.  The system then allowed cytoplasmic perimeters and 
nuclear outlines to be traced, and these parameters could be numerically calculated.  This 
study showed that nuclear form factor (a value calculated by measuring nuclear perimeter 
and nuclear area) was not statistically different (p < 0.01) between the cytologic and 
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histopathologic samples.  In a subsequent study, Strefezzi, Xavier, and Catao-Dias 
(2003),40 evaluated 24 cutaneous mast cell tumors with automated nuclear morphometry.  
Tumors had been previously assigned a histopathologic grade.  Parameters such as 
nuclear area, mean diameter, and perimeter were measured via morphometry and these 
data showed that those values did increase with increasing severity of histopathologic 
grade.  However, statistical significance was only reached between grade II and grade III 
tumors, and between grade I and grade III tumors, using specific staining techniques.  A 
similar study was performed by Maiolino, Cataldi, and Paciello et al (2005)41 on 35 mast 
cell tumors analyzed via nuclear morphometry.  Results were similar to the Strefezzi 
(2003)40 study in that some parameters (mean nuclear area and mean nuclear perimeter) 
were different between mast cell tumors of varying histologic scores.  However, these 
differences were only significant between grade I and grade III tumors and between grade 
II and grade III tumors.  
 
Cytologic correlation with histopathology  
Correlation between cytologic markers and histopathology in other tumor types 
has been evaluated.  In human oncology, Khan, Haleem, and Hassani et al (2003)42 
identified 6 distinct cytologic criteria that showed excellent correlation to histopathologic 
grade in human ductal carcinoma in situ: pleomorphism, nuclear size, nuclear margin, 
nucleoli, naked tumor nuclei, and mitotic count (p < 0.001 for each criteria).  Limited 
work in the veterinary field has examined the potential application of advanced staining 
techniques for markers of cellular proliferation in cytologic samples obtained from 
tumors and lymph nodes.  Vajdovich, Psader, and Toth et al (2004)43 investigated the use 
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of AgNOR staining in cytology and histopathology of canine lymph nodes in 16 dogs 
diagnosed with lymphoma versus healthy dogs.   Results showed that AgNOR scores in 
both cytology and histology samples were significantly different (p < 0.001) between 
control dogs and dogs with lymphoma.  Kravis, Vail, and Kisseberth (1996)44 found a 
similar linear relationship (p < 0.001) between AgNOR staining of fine needle aspirates 
and histopathology sections from 32 canine mast cell tumors.  They also demonstrated 
that AgNOR staining of cytology samples correlated to tumor histologic grade.  
 
Feline disease  
Histologic grade as determined by the Patnaik1 scale has no influence on survival 
time in cats with cutaneous mast cell disease.45  This study by Molander-McCrary, 
Henry, and Potter et al (1998) examined 32 cases of feline mast cell tumors that were 
treated surgically.  Completeness of surgical excision and histologic grade had no 
correlation to survival time or recurrence of disease.  Johnson, Schulman, and Lipscomb 
et al (2002)46 evaluated pleomorphic mast cell tumors in 15 cats.  Pleomorphic tumors 
contained mast cells with widely variable cellular and nuclear diameters.  The large 
majority (79%) of cats had no local recurrence, no additional cutaneous tumors, and no 
metastasis in the follow up period (range 5-25 months).  Feline cutaneous mast cell 
tumors are considered to have a largely benign course. 
 
Summary 
In summary, mast cell tumors have a complicated, variable disease progression.  
While these tumors are commonly diagnosed in veterinary medicine, the prediction of 
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biologic behavior and the ability to reliably predict their disease progression remain 
problematic.  The numerous limitations of the previous studies to date make comparisons 
between these studies difficult.  Histopathology has long been considered the gold 
standard for prognosis of canine mast cell tumors but cytologic criteria may be equally 
important.  The goal of the study described here was to evaluate specific cytologic 



















STUDY DESIGN AND MATERIALS AND METHODS 
 
The study design was retrospective in nature, with cases that had a cytologic 
diagnosis of mast cell tumor identified from computerized searches of Iowa State 
University  medical records and pathology reports in patients evaluated at the College of 
Veterinary Medicine.  All cytology samples included in the study were evaluated at Iowa 
State University College of Veterinary Medicine from 1995 – 2000.  Clinical cases were 
presented to the teaching hospital and cytopathology samples were mailed in to the 
clinical pathology laboratory for evaluation.  All cases were required to have at least one 
cytology slide of the tumor available for review.  All slides were required to have at least 
10 high power fields available for diagnostic evaluation.  One microscope was used for 
cytologic evaluation the entire study (Nikon, Alphaphot 2, YS2 with 4x, 10x, 40x, and 
100x (oil immersion) objectives).   
 Location of the sample was recorded, either as an aspirate from a discrete, 
cutaneous mass, or from aspiration of a lymph node.  The sample processing was also 
recorded as either a direct smear (via fine needle aspiration or needle fenestration) or as a 
cytospin sample.  All samples were stained by clinical pathology laboratory personnel 
with Wright-Giemsa stain using a standard protocol. 
 Fourteen separate cytologic criteria were evaluated on each slide.  Cytologic 
criteria that are well known to be universal indicators of malignancy (e.g. nuclear to 
cytoplasmic ratio)47 were initially included.  Criteria unique to mast cells (e.g. granule 
staining properties) were additionally included after discussion with board certified 
pathologists.  Table 2 lists the individual cytologic criteria and their associated 
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parameters evaluated during this study.  The individual criteria have been grouped into 
larger sections for ease of understanding.   
Table 2.  Cytologic criteria evaluated in 52 cases of mast cell tumors. 
 
Mast Cell Granule Characteristics Associated Blood Cell Parameters 
          Granule staining properties           Red blood cells 
                    Well                     Lowest number  
                    Intermediate                     Highest number 
                    Poor           Neutrophils 
          Granule percentage within the cell                     Lowest number 
                    Lowest percentage                     Highest number 
                    Highest percentage           Eosinophils 
Cellular Proliferation Criteria                     Lowest number 
          Multinucleated cells                     Highest number 
                    Lowest number Mast Cell Cytoplasmic Criteria 
                    Highest number           Cytoplasm border description 
          Binucleated cells                     Clear and distinct 
                    Lowest number                     Intermediate 
                    Highest number                     Variable and indistinct 
          Mitotic figures           Overall cell size (estimated in microns) 
                    Lowest number                     Smallest 
                    Highest number                     Largest 
Mast Cell Nuclear Criteria  
          Nuclear size (estimated in microns)  
                    Smallest  
                    Largest  
          Predominant nuclear shape  
                    Round  
                    Intermediate  
                    Irregular  
          Presence and prominence of nucleoli  
                    Few and indistinct  
                    Intermediate  
                    Multiple and prominent  
          Nuclear to cytoplasmic ratio  
                    Uniform and fixed  
                    Variable  
                    Highly variable  
 
The reviewer was blinded to the histologic grade of each sample.  Some cytologic criteria 
(n = 5) were calculated as an overall average while other criteria (n = 9) were recorded as 
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the highest and lowest values documented per slide (each slide having at least 10 high 
powered fields available for diagnostic evaluation).  Table 3 lists the cytologic criteria 
grouped by method of evaluation.   
Table 3. Grouping of mast cell cytologic criteria based on method of evaluation 
Criteria determined as overall average  
Granule staining properties 
Predominant nuclear shape 
Presence and prominence of nucleoli 
Nuclear to cytoplasmic ratio 
Cytoplasm border  
Criteria determined as low to high range  





Red blood cells 
Neutrophils 
Eosinophils 
Overall cell size 
 
The methods of evaluation were developed with statistician consultation.   
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Granule staining was semiquantitated by evaluating at least 10 high powered 
fields on a slide.  If the majority of granules were well stained, then the slide received a 
score of 1.  Intermediate staining granules received a score of 2, and poorly stained 
granules received a score of 3.  Figure 1 shows 3 well stained mast cells. 
 
 
Figure 1. Mast cell granule staining.  Three well stained mast cell tumors showing 
abundant dark purple granules. (Wright Giemsa stain, magnified, 100x) 
 
Clearly, granules within the cytoplasm might obscure nuclear and cytoplasmic 
characteristics of a particular cell.  In that event, that cell was not included in the 
determination of cytologic criteria for that particular high powered field.   
Nuclear shape was determined as an overall score for each slide after evaluating 
at least 10 high powered fields.  If the majority of the nuclei were determined to be 
round, regular, and well defined, then the slide was given a score of 1 for that particular 
criteria.  If the predominant nuclear shape was judged to be irregular, with the nuclei 
having indentations, or an irregular outer margin, then the slide was given a score of 3.  
Lastly, if the nuclei in the majority of mast cells were judged to be variable between the 2 
extremes of round (scored as 1) and irregular (scored as 3), then the slide was given a 




Figure 2. Mast cell nuclear shapes: round, smooth and well defined (white arrow) and 
irregular with indentations (black arrow). (Wright Giemsa stain, magnified, 100x) 
 
Nucleoli characteristics were investigated on cytology samples and judged to be 
either indistinct and few, intermediate, or multiple and prominent.  These slides were 
scored in a similar fashion with one overall score assigned to each slide.  Indistinct and 
few nucleoli were scored as 1, intermediate as 2, and multiple and prominent nucleoli 
scored as 3.  Figure 3 shows a mast cell with a single, clearly defined nucleolus. 
 
 
Figure 3.  Mast cell showing a single, prominent, dark purple nucleoli (black arrow) 
within pale blue nucleus. (Wright Giemsa stain, magnified, 100x) 
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Nuclear to cytoplasmic ratio was determined as a mean score for each slide 
(average of at least 10 high powered fields).  If the nuclear to cytoplasmic ratio was 
judged to be fixed and uniform, the slide received a score of 1.  If the ratio was variable, 
the slide received a score of 2.  If the nuclear to cytoplasmic ratio was judged to be highly 
variable across the slide, the slide was given a score of 3.   
Cytoplasm border was the last parameter where overall impression of the slide 
was recorded as a mean score.  If the cytoplasm was judged to be clear and distinct, then 
a score of 1 was given.  If the cytoplasm was determined to be somewhat intermediate, 
then a score of 2 was recorded.  A score of 3 was given when the cytoplasm was 
determined to be overall variable and indistinct. 
Seven criteria were recorded as both a low and high number: granule percentage 
within the cell, multinucleated and binucleated cells, mitotic figures, red blood cells, 
eosinophils, and neutrophils.  Two criteria were recorded as smallest and largest size: 
nuclear size and overall cell size.   
Granule percentage within the cell was evaluated with a lowest and highest 
number.  The lowest number was defined as the lowest or smallest proportion of 
cytoplasm that contained granules.  The lowest estimation was 1/8th (or 0.125) percentage 
of the cell contained granules.  The highest proportion was seen in those cells that 
appeared to be completely filled with granules, and in those cases, the value of 99% 
(0.99) was assigned.  Figure 4 shows an example of a mast cell with the highest granule 







Figure 4.  Mast cell granule percentage.  Mast cell with the highest granule percentage 
recorded (99%). (Wright Giemsa stain, magnified, 100X) 
 
Multinucleated cells and binucleated cells were counted in a similar fashion, with 
the lowest and highest number being recorded on each slide.  In a similar manner, mitotic 
figures were counted as a low and high number.  Figure 5 shows an example of a 
binucleated mast cell.   
 
 
Figure 5.  Binucleated mast cell (black arrow). Nuclei appear as pale blue, symmetric 
structures within pale pink / purple cytoplasm. (Wright Giemsa stain, magnified, 100x) 
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Counts were obtained for the lowest number of cells visible in each high powered 
field and the highest number of cells visible in each high powered field for red blood 
cells, neutrophils, and eosinophils,.  The lowest value assigned for any of the cell lines 
was 0.  The highest value was given when the field had cells that were too numerous to 
count, in which the value of 999 was assigned.  This value was used to aid in statistical 
analysis of the data.  Figure 6 shows a mast cell and associated blood constituents. 
 
 
Figure 6.  Associated blood cell components.  Mast cell (white arrow), red blood cells 
(black arrow), and an eosinophil (blue arrow). (Wright Giemsa stain, magnified, 100x) 
 
When evaluating cell size, the smallest and largest cell sizes seen in an average of 
10 high powered fields were recorded.  The cell sizes were measured by comparing the 
diameter of the mast cells to adjacent red blood cells, which are estimated to have a 
diameter of 7 microns (in the dog).  Figure 7 shows the measurement of a mast cell with 




Figure 7.  Mast cell size.  Mast cell (white arrow) measuring approximately 21 microns 
compared to a nearby red blood cell (black arrow) measuring 7 microns. (Wright Giemsa 
stain, magnified, 100x) 
 
Nuclear size was measured in like manner with the smallest nucleus and the 
largest nucleus measured and recorded.   These cytologic criteria were developed 
prospectively and were only minimally modified after the start of the study.   
The cytologic evaluation technique was as follows.  Each slide was initially 
scanned at low-power (10x objective) to determine slide quality, cellularity, and staining 
quality.  Once the slide was determined to be of overall acceptable diagnostic quality, the 
slide was evaluated under high-powered (100x-oil) objective.  Each high-powered field 
was initially scanned for diagnostic quality (cellularity, staining quality, absence of cell 
clumping) and at least 10 separate, distinct high-powered fields were identified per slide.  
If there were not at least 10 diagnostic fields present, the slide was removed from the 
study.  Once the slide was reviewed and determined to be acceptable, the cytologic 
criteria were individually measured.  The order in which the cytologic criteria were 
 32 
evaluated and recorded was consistent throughout the study.  The order of data collection 
and recording is presented in Table 4. 
Table 4.  Collection and recording order of mast cell cytology data. 
Lymph node vs. discrete mass 
Granule staining 
Percentage of cell filled with granules 
Cell size  
Nuclear size 
Nuclear shape  
Cytoplasm border 
Binucleate cells  
Multinucleate cells  
Mitotic figures  
Eosinophils  
Neutrophils  
Red blood cells  
Nucleoli  
Nuclear : cytoplasmic ratio 
Smear vs. cytospin 
 
Data sheets were developed to record cytologic findings and the end results were 
recorded to a spreadsheet for statistical analysis.  Each criteria was assigned a numeric 
value for statistical analysis at the end of data collection.  As an example, if the cytology 
sample was obtained from a cutaneous mass, the data was recorded as 1 for mass and 0 
for lymph node on the spreadsheet.  Kendal-Tau non-parametric analysis was performed 
on the initial data set and the value for statistical significance was set at p < 0.1.  This p 
value was chosen in an attempt to increase the number of statistically significant findings.  
Logistic regression was then performed on those cytologic criteria identified as 
significant from the initial statistical analysis.  All statistical analysis was performed with 
a commercially available statistical software package (JMP, Cary, NC, version 4). 
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RESULTS AND DISCUSSION 
 
Fifty two total cases fulfilled the study inclusion criteria.  Thirty nine of the 52 
cases had multiple slides available, and so 132 total slides were reviewed.  Eighty slides 
were  direct smears, and 52 slides were cytospin samples.  All cytologic criteria were 
evaluated on each of the 132 slides.  Twenty six of the cases had concurrent 
histopathologic diagnosis and histologic grade recorded, based on the Patnaik1 scale.  
Twenty of the those 26 cases had multiple cytology slides, so there was a total of 64 
histologic grades. 
The histologic grades of the tumors that were evaluated were as follows: grade I 
tumors (7/26 = 26.9%), grade II tumors (14/26 = 53.9%), and grade III tumors (5/26 = 
19.2%).  All statistically significant findings between cytologic criteria and histologic 
grade were identified from samples that were processed as cytospin samples.  Four 
cytologic factors were determined to be significantly related to histologic grade in the 
initial, non-parametric analysis.  Those factors were: presence of multinucleated cells 
[Kendal-Tau value = 0.42, p-value = 0.04], mitotic index [Kendal-Tau value = 0.39, p-
value = 0.06], large cell size [Kendal-Tau value = 0.31, p-value = 0.09], and nuclear 
shape [Kendal-Tau value = 0.45, p-value = 0.03].  Once these values had been identified, 
logistic regression was performed on those four cytologic criteria and three cytologic 
factors were determined to be statistically significant.  Those factors were: presence of 
multinucleated cells (p-value = 0.02), large cell size (p-value = 0.07), and nuclear shape 
(p-value = 0.06).  The resultant value for mitotic index was determined to be p = 0.1, 
which did not reach statistical significance.   
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The recorded values on cytologic analysis for multinucleated cells ranged from a 
low of 0 cells to a high of 3 cells.  The lowest number of multinucleated cells was not 
determined to be significant, but the highest number of multinucleated cells did reach 
statistical significance.   The distribution of multinucleated cell numbers is illustrated in 
figure 8.    
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The presence of an increased number of multinucleated cells was positively 
correlated to increasing histologic grade (p-value = 0.02). 
 The largest mast cells measured ranged from 21-70 microns in diameter.  The 
distribution of mast cell sizes are illustrated in figure 9.  Results of correlation analysis 
indicated that larger cell size correlated positively to increasing histologic grade (p-value 
= 0.07).       
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 The final cytologic factor that was determined to have a statistically significant 
relationship to histologic grade was nuclear shape.  The distribution of nuclear shape 
scores are illustrated in figure 10.  The presence of irregular nuclear shape positively 




















   
In the current study, 3 cellular characteristics were found to be significantly 
correlated to histologic grade: presence of multinucleated cells, large cell size, and 
irregular  nuclear shape.  These cytologic and histologic criteria would seem to correlate 
well based on previous descriptions of the mast cells in the histologic scoring system.  A 
summary of the descriptions for histologic grades I, II, and III for mast cell tumors (as 
defined by Patnaik)1 is provided in Table 5.   
Regarding histologic evaluation, multinucleated cells are more commonly 
observed in grade III mast cell tumors.  In the current study, the presence of 
multinucleated cells was also associated with increasing histologic grade.  The same can 
be said for the presence of large cell size (giant cells) in histologically confirmed grade 
III tumors.  Furthermore, cytologically the present study demonstrated that the largest 
mast cells were seen in grade III tumors.   
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Table 5. Summary of Patnaik histologic grading system for mast cell tumors. 
Grade Histologic Description 
I Cells are round and similar in size and shape and have distinct cytoplasmic 
borders with fine, intracytoplasmic granules; nuclei are round and chromatin is 
condensed; no mitotic cells are noted. 
II Cells are moderately variable in size and shape; cells are round to ovoid and there 
are scattered giant cells and spindle cells; most cells have distinct cytoplasm with 
fine, intracytoplasmic granules; in some, the cytoplasm is indistinct and granules 
are large and hyperchromatic; nuclei are round to indented with scattered 
chromatin and some nuclei have multiple nucleoli; mitotic figures are present, but 
rare. 
III Cells have wide variety in shape and size, including round, ovoid, or spindle 
shaped; cytoplasm is indistinct with fine, intracytoplasmic granules or granules 
are not obvious; binucleated cells are common; giant cells and multinucleated 
cells are seen; mitotic cells are also common. 
 
Both multinucleated cells and large cell size can be considered relatively 
objective criteria.  Simplistically, the presence of multinucleated cells may be ascertained 
as a simple ‘present or absent’ determination.  Cell size may be measured directly, by use 
of an eyepiece micrometer, or can be estimated by comparing the diameter of mast cells 
to the diameter of other cells (such as red blood cells = 7 microns) in the same 
microscope field.  
On the other hand, nuclear shape is a less objective parameter, as compared to 
multinucleated cells and cell size.  This parameter was determined as an opinion of the 
predominant nuclear shape on the slide.  There was no defined measurement of nuclear 
shape or objective comparison to other parameters on the slide.   
It is noteworthy that no granular characteristics evaluated in this study (e.g., 
granule staining properties or granule percentage within the cell) were significantly 
correlated to prognosis.    Based on the histologic description, especially of the staining 
characteristics of grade III tumors, one might have expected to see some positive 
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relationship between granule characteristics and histologic grade.  However, no such 
relationships were discovered.   
 Another cytologic criteria that was examined was the presence of other blood cell 
constituents, such as red blood cells, eosinophils, and neutrophils.  Since mast cell tumors 
may have associated hemorrhage from tissue invasion, as described in the Patnaik1 
grading scheme, cytologic evidence of red blood cells may or may not correlate with 
histologic grade.  Eosinophils and neutrophils were evaluated for somewhat similar 
reasons, namely due to associated hemorrhage (especially with neutrophils), or 
concurrent inflammation.  Eosinophils are commonly identified in cytologic and 
histologic samples from mast cells tumors.48,49  While the presence of eosinophils has not 
been evaluated in correlation with histologic grade, cytologic evaluation of eosinophil 
numbers has also not been determined.  Regardless, in this current study, there was no 
significant relation between mast cell histologic grade and cytologic red blood cell, 
neutrophil, or eosinophil numbers. 
 While there were cytologic nuclear criteria that did correlate with histologic 
grade, namely nuclear shape and multinucleated cells, there were other nuclear criteria 
that did not have a statistically significant relationship identified.  The other criteria 
included nuclear size, nuclear to cytoplasmic ratio, binucleate cells, presence and 
prominence of nucleoli, and the presence of mitotic figures (or mitotic index).  The 
smallest nucleus measured 7 microns, and the largest was estimated to be 35 microns.  
Anisokaryosis (variation in nuclear shape) is considered to be a criteria of malignancy.  
We hypothesized that evidence of anisokaryosis seen on cytology samples might 
correlate to worsening histologic grade.  However, this association was not found to be 
 39 
significant.  Even though increased nuclear to cytoplasmic ratio is a known cytologic 
criteria of malignancy, this factor in this cytologic study did not correlate to 
histopathologic grade.   
Binucleated cells are typically included as part of the histologic description of 
grade III mast cell tumors.  The lowest number of binucleated cells seen per high 
powered field in this study was 0, and the highest number was 4.  Neither of these 
correlated to histopathologic grade. 
The presence of irregular, or multiple nucleoli is considered another cytologic 
criteria of malignancy.  There was no significant correlation found between nucleoli 
criteria and histologic grade of mast cell tumors. 
The lowest value recorded for mitotic figures in our samples was 0, and the 
highest was 3.  In the initial (univariate) analysis, mitotic index did attain statistical 
significance.  However, this significance did not survive multivariate analysis so 
ultimately, neither binucleated cells, presence and prominence of nucleoli, nor mitotic 
index were shown to be significantly correlated to histologic grade.   
Increased nuclear activity would appear to correlate to increased biologic 
behavior and thus, potentially, increased histologic grade.  While various specialized 
staining techniques (e.g., AgNOR staining) have been shown to indicate increased 
nuclear activity, it may be difficult to demonstrate increased nuclear activity on the basis 
of routine cytologic evaluation of nuclear morphologic criteria.  In this study, nuclear 
shape and the presence of multinucleated cells were statistically significant nuclear 
morphologic criteria that correlated to histologic grade. 
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The other, primarily cytoplasmic characteristic that was evaluated was the 
cytoplasm shape and border description.  When reviewing the descriptions of histologic 
grade in the Patnaik1 scale, cytoplasmic descriptions are present with each grade (see 
Table 5).  Thus, it was decided to include cytoplasm in the cytologic evaluation, to 
determine a possible relationship to histologic grade.  This was another parameter where 
overall impression of the slide was recorded as a mean score.  The data of the present 
study showed that this cytoplasmic parameter did not attain statistical significance. 
In summary, 3 cytologic characteristics significantly correlated to histologic 
grade: presence of multinucleated cells, large cell size, and irregular nuclear shape.  
These cellular criteria are all included in the current histologic grading scale of mast cell 
tumors, so these correlations were not surprising.  However, significant correlations were 
only found for 3 of the 14 studied cytologic criteria.     
 Several questions come to mind in explaining why certain cytologic criteria were 
not positively correlated to histopathologic grade.  One limitation of our study is that 
sample numbers were small, as compared to earlier published reports.  The cytology 
samples of the present report were small, and the tissue samples that were available for 
histopathologic evaluation were even less numerous.  Thus, there were fewer 
comparisons available for certain tumor grades and there were several reasons for the 
small number of tissue samples.  First, some cytology samples were obtained as mail in 
samples without the benefit of histopathologic examination performed at ISU.  Secondly, 
there were no histopathology samples for  some animals that had recurrent mast cell 
tumors, that had metastatic disease, or that were otherwise not surgical candidates.   
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Certain cytologic criteria were also more difficult to ascertain because of the  
subjective nature of the evaluation.  Factors that were subjectively measured versus being 
directly measured included the nuclear to cytoplasmic ratio, the granule staining 
properties and granule percentage within the cells, the presence and prominence of 
nucleoli, the nuclear shape, and the cytoplasmic border description.  It is possible that 
more precise differentiations, via objective criteria, for cytologic parameters might have 
led to greater histologic correlations.  As an example, nucleoli were placed into 1 of 3 
main classifications: few / indistinct, intermediate, or multiple / prominent.  Perhaps more 
distinct differentiations could have allowed for a more precise description of this 
variable, such as: no nucleoli noted, 1-2 nucleoli visible, more than 2 nucleoli present 
within the nucleus.    
Another study limitation is that only one observer recorded all cytologic 
evaluations.  As evidenced by the previous description of variations in histopathologic 
grading between pathologists, there may be distinct differences in the manner in which 
slides are read and tissues are evaluated.  The study could be strengthened by having 
multiple observers review the slide sets independently and determine what, if any, 
significant criteria remained after this “consensus” independent review.   
Admittedly, this was a retrospective study with defined limitations.  These 
limitations included a lack of standardization of sample procurement; a lack of follow up 
with histopathologic evaluation; incomplete medical records and / or incomplete medical 
record coding that limited the number of cases identified through medical record 
searches.  All the cytologic criteria that were deemed significant in this study were 
observed on samples undergoing cytospin preparation.  The cytospin technique increases 
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the number of cells available for evaluation in microscopic fields, as compared to direct 
smear samples.  While cytospin slide preps concentrate cell populations and maintain cell 
integrity, this cytologic preparation method is not routinely available to most veterinary 
practitioners.  One of the stated advantages of cytologic evaluation is the ease of sample 
procurement and the ability of general practitioners to obtain diagnostic samples.  An 
obvious follow up to the current study is to prospectively enroll cases of cutaneous mast 
cell tumors and evaluate increased numbers of direct smear and cytospin samples.  This 
would address the question as to whether cytologic criteria are only significantly related 
to histopathologic grades in cytospin samples and would be of relevance to veterinary 














GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In conclusion, there are a few known, accepted, prognostic factors for clinical 
progression of mast cell tumors.  These factors include histologic grade, presence of 
clinical or systemic signs of mast cell disease, and increased expression of cellular 
markers of proliferation.  To date, while there has been excellent correlation shown 
between cytologic and histopathologic diagnosis of mast cell tumors,38 there has not been 
a proven correlation between defined cytologic criteria and histopathologic grade of mast 
cell tumors.  This study identified 3 defined cytologic criteria based on cytospin samples 
with statistically significant relations to histologic grade including the presence of 
multinucleated cells, the presence of large cell size, and the presence of an irregular 
nuclear shape. 
 Ideally, prospective evaluation of cytologic criteria of mast cell tumors could be 
initiated which included evaluation of the following parameters: sampling technique 
(e.g., needle fenestration versus needle aspiration techniques) and follow up 
histopathologic examination on all tissues (when deemed appropriate for the patient).  
This would assist in answering (1) whether there is value in direct smear preparations (as 
compared to cytospin samples); (2) whether the initial findings presented in this study 
can be confirmed by a separate, independent observer; (3) whether there are other 
cytologic criteria that correlate to histology; and (4) whether those criteria that have been 
identified might show greater significance through increased sample numbers. 
 Future investigations, primarily centered on those factors indicating cellular 
proliferation, should be evaluated.  AgNOR, PCNA, and Ki-67 staining could be 
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performed on cytology samples.  There would be great clinical impact if there would be a 
correlation to cytologic criteria, histologic grade, and known indicators of cellular 
proliferation.  This could be even more significant if evidence was found to further 
elucidate grade II mast cell tumors.  In the context of a prospective study, disease free 
intervals, survival times, and time to recurrent disease could be more readily documented, 
thus increasing the potential prognostic value of cytology.  This could also allow for 
complete documentation of other variables such as dog breed, tumor location, tumor size, 
and the presence of associated clinical signs.  If such valuable information could be 
obtained on the basis of a needle aspiration of cytology samples, then patient morbidity 
would be significantly decreased since surgical planning and adjunctive therapy could be 
more appropriately tailored to the patient.  This information could then translate directly 
into defined therapeutic interventions.   
 While this study is limited in scope and there are some weaknesses in study 
design, it is notable that these data identified distinct cytologic criteria that significantly 
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